When does the ixekizumab patent expire?
Ixekizumab (Taltz) patents and exclusivity timelines depend on the country and the specific patent family covering each use (drug substance, drug product, formulations, and methods). Patent expiry is not a single global date; there can be multiple expiries across different jurisdictions and additional periods of exclusivity on top of patent terms.
If you tell me the country (for example, US, EU/UK, Canada, Japan, or Australia), I can narrow this to the relevant timeline for that market.
What patents matter for ixekizumab—drug or use patents?
For biologics like ixekizumab, exclusivity and “patent expiry” usually get driven by:
- patents covering the biologic molecule (drug substance),
- patents covering the finished product (drug product),
- patents covering specific indications or dosing/methods,
- regulatory exclusivity that can extend market protection even when some patents expire.
Because different patent types expire on different dates, the “last” date that blocks competition can be later than the first patent to expire.
Can a biosimilar enter before all patents expire?
Yes. Biosimilars can sometimes launch before every patent in the family expires if they do not infringe the remaining active patents (or if those patents are invalidated or not asserted successfully). In other cases, patent disputes can delay launch even when biosimilar approval is granted.
What about US-specific “exclusivity” timing?
In the US, biologics rely on both patent terms and the Biologics Price Competition and Innovation Act (BPCIA) exclusivity framework. That can create delays that go beyond patent expiry dates alone. A precise answer needs the specific ixekizumab reference product exclusivity and patent list for the relevant patents.
Which region should you base the expiry date on?
If you’re looking for a usable “expiry date,” you need the jurisdiction:
- US: patent and BPCIA exclusivity/trigger dates
- EU: supplementary protection can differ by member state and timeline
- UK: post-Brexit rules differ from EU in some respects
- other countries: patent term adjustments and data exclusivity vary
Quick way to get the exact date you want
Reply with:
1) the country (or countries),
2) whether you mean “first biosimilar approval possibility” or “last patent/exclusivity block,”
3) if you want indication-specific timing (for example, plaque psoriasis vs psoriatic arthritis).
Then I can provide the most relevant ixekizumab patent/exclusivity expiry timeline for that exact scope.